Related Experiment Video
Updated: Aug 7, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Bergamot (Citrus bergamia) preserves cardiac structure and function and modulates myocardial redox and metabolic
Matheus Antonio Filiol Belin1, Jordanna Cruzeiro2, Aline Nunes3
1Botucatu Medical School, São Paulo State University (UNESP), Botucatu, 18618-687, Brazil; School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, 58105, United States.
Insights
Bergamot supplementation improved cardiac function and reduced oxidative stress in obese rats, despite persistent obesity. This suggests potential benefits for heart health in metabolic disease, independent of weight loss.
Area of Science:
- Cardiology
- Metabolic Syndrome
- Nutraceuticals
Background:
- Obesity is a major risk factor for cardiac remodeling and dysfunction.
- Oxidative stress, inflammation, and metabolic disturbances are key mechanisms linking obesity to heart disease.
- Citrus bergamia (bergamot) shows promise for cardiometabolic risk factors, but its direct cardiac effects require investigation.
Purpose of the Study:
- To evaluate the effects of bergamot supplementation on cardiac structure, function, and metabolic status in a rat model of diet-induced obesity.
Main Methods:
- Wistar rats were randomized into Control, Obese, and Obese+Bergamot groups for 20 weeks.
- Bergamot was administered orally at 250 mg/kg/day to the Obese+Bergamot group.
- Cardiac structure and function, oxidative stress markers, inflammatory cytokines, and cardiac metabolites were assessed.
Main Results:
- Bergamot attenuated cardiac remodeling and preserved systolic and diastolic function in obese rats.
- Supplementation reduced oxidative damage markers (malondialdehyde, protein carbonyls) and cardiac inflammation (TNF-α, IL-10).
- Metabolic profiling revealed alterations in polyamines, fatty acids, and purine metabolism, with increased spermine and inosine.
Conclusions:
- Bergamot supplementation offers cardiac protection in diet-induced obesity, improving cardiac function and reducing oxidative stress and inflammation.
- These benefits occur independently of significant weight loss or restoration of NRF2 pathway and NAD+/NADP+ levels.
- Specific metabolic changes, including elevated spermine and inosine, may be associated with bergamot's cardioprotective effects.
Abstract:
Obesity promotes cardiac remodeling and dysfunction through oxidative stress, inflammation, and metabolic disturbances. Citrus bergamia (bergamot) has shown beneficial effects on obesity-related cardiometabolic risk factors, but its cardiac effects remain unclear. We evaluated bergamot supplementation in a rat model of diet-induced obesity using integrated assessments of cardiac structure and function, redox and inflammatory status, biogenic amines, fatty acids, and metabolites. Wistar rats (n = 54) were randomized to Control, Obese, or Obese + Bergamot groups for 20 weeks; bergamot was administered by gavage at 250 mg/kg/day. Animals in both obese groups had higher body weight (p < .01) and adiposity index (p < .0001) than controls, confirming diet-induced obesity. Untreated obese rats also exhibited higher systolic blood pressure, cardiac remodeling, oxidative damage, higher cardiac TNF-α and IL-10 concentrations, and reduced NRF2 expression (p < .05). Bergamot attenuated cardiac remodeling, preserved systolic and diastolic function (p < .05), reduced malondialdehyde (p < .05), protein carbonyls (p < .0001), and cardiac TNF-α and IL-10 concentrations (p < .05), and increased ferric reducing antioxidant power (p < .01). Exploratory cardiac metabolic profiling showed partial recovery of putrescine and spermidine, higher spermine and histamine concentrations (p < .05), lower serotonin monoforms (p < .05), higher arachidonic acid abundance (C20:4n6; p < .05), and higher inosine abundance (p < .05) following bergamot supplementation. Bergamot-associated cardiac preservation occurred despite persistent obesity and without restoration of NRF2 expression, the NRF2/KEAP1 ratio, or myocardial NAD+ and NADP+ concentrations. Changes in polyamine, fatty acid, and purine-related profiles, including higher spermine and inosine, identify candidate metabolic features associated with this response but do not establish these metabolites as causal mediators.
Related Concept Videos
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
